Patient characteristics and prior therapy
| Characteristic | N (%) |
|---|---|
| Median Age (range) | 65 (57–72) |
| Gender | |
| Male | 13 (93%) |
| Female | 1 (7%) |
| Histology | |
| Clear cell | 13 (93%) |
| Papillary | 1 (7%) |
| ECOG | |
| 0 | 9 (64%) |
| 1 | 5 (36%) |
| IMDC risk group | |
| Favorable | 1 (7%) |
| Intermediate | 12 (86%) |
| Poor | 1 (7%) |
| Metastatic sites | |
| Lymph nodes | 8 (57%) |
| Bone | 8 (57%) |
| Lung | 7 (50%) |
| Liver | 3 (21%) |
| Number or prior therapies | |
| 1 | 12 (86%) |
| 2 | 1 (7%) |
| 3 | 1 (7%) |
| Most recent therapy | |
| Sunitinib | 8 (57%) |
| Axitinib | 3 (21%) |
| Pazopanib | 2 (14%) |
| HIF-2a inhibitor | 1 (7%) |
| Best response to most recent therapya | |
| PR | 3 (21%) |
| SD | 9 (64%) |
| PD | 1 (7%) |
| Median duration on most recent therapy (months)a | 18 (3–100) |
aMissing for one patient